Additive effect of cyclosporine and verapamil on the inhibition of activation and function of human peripheral blood mononuclear cells.
Weir
M R
MR
Department of Internal Medicine, University of Maryland Hospital, Baltimore 21201.
Peppler
R
R
Gomolka
D
D
Handwerger
B S
BS
D000255:Adenosine Triphosphate / Q000096:biosynthesis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology; D017252:CD3 Complex; D003524:Cyclosporins / Q000494:pharmacology*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects*; D007113:Immunity, Innate / Q000187:drug effects; D007165:Immunosuppression Therapy; D066298:In Vitro Techniques; D007694:Killer Cells, Natural / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000187:drug effects*; D008213:Lymphocyte Activation / Q000187:drug effects*; D010835:Phytohemagglutinins / Q000494:pharmacology; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects; D014700:Verapamil / Q000494:pharmacology*
D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D003524:Cyclosporins; D010835:Phytohemagglutinins; D000255:Adenosine Triphosphate; D014700:Verapamil